Substitute for f	form 1449A-B/PTO	С	omplete if Known	
		Application Number	09/811,162	
INFORMAT	ION DISCLOSURE	Filing Date	March 16, 2001	
I STATEMEN	NT BY APPLICANT	First Named Inventor	MARTINS-GREEN	N, Manuela
[7]		Group Art Unit	1647	\ <u>\</u>
د		Examiner Name	Regina M. DeBerr	ry 🐼
4 2002 S use as n	nany sheets as necessary)	Attorney Docket Number	407E-000500US	, 20,
1 4/		Date Submitted	October 31, 2002	
MRK OFFICE				
ARK	l	U.S. PATENT DOCUMENTS		Á
	U.S. Patent Document	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,

		U.				
	U.S. Patent Doo	cument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,	
Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal	
		_				
		Cite Number	Cite U.S. Patent Document Kind Code	Cite Number Kind Code Cited Document	U.S. Patent Document Name of Patentee or Applicant of Cited Number Kind Code Cited Document Cited Document	

		-		FOREIGI	N PATENT DOCUMEN	ΓS		
Examiner Initials	Cite No.	Office	Foreign Patent Docu	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
An	AA	JP	11-43445	Α	Hatake, et al.	02-16-1999		
KW)	AB	JP	11-21296	Α	Hatake, et al.	01-26-1999		
1 20								

		OTHER PRIOR ART. MON PATENT LITERATURE POOLINENTS	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
AC Baggiolini, M., Dewald, B., and B. Moser. 1997. Human chemokines: an update. Annu. Rev. Immunol. 15:675-705.			
	AD	Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.R., Zlotnik, A., and T.J. Schall. 1997. A new class of membrane-bound chemokine with a CX3C motif. <i>Nature(Lond.)</i> 385: 640-644.	
	AE	Belperio, J.A., Keane, M., Arenberg, D., Addison, C., Ehlert, J., Burdick, M.D., and R. Strieter. 2000. CXC chemokines in angiogenesis. <i>J. Leukoc. Biol.</i> 68:1-8.	
	AF	Brown, L., Dubin, D., Lavigne, L., Logan, B., Dvorak, H., and L. Van de Water.1993. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. <i>Am. J. Pathol.</i> 142:793-801.	
	AG	Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. <i>Nature Med.</i> 6:389-95.	
	АН	Clark, R. 1993. Basics of cutaneous wound repair. J. Dermatol. Surg. Oncol. 19:693-706.	
	Al	Clark-Lewis, I., Kim K., Rajarathnam, K., Gong, J., Dewald, B., Moser, B., et al. 1995. Structure-activity relationships of chemokines. J Leukoc. Biol. 57:703-711.	
Ri	AJ	Coffin, C., Dehner, L., and J. Meis-Kindblom. 1998 Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Seminars in Diagnostic Pathology 15:102-110.	

√ /			\sim ℓ				
Examiner Signature	1 mina	MI		Date Considered	3	101	0,3
	- // 	/				777	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				A	pproved for use through 10/31/99. OMB 0651-0	031			
5	Subsi	titute fo	r form 1449A-B/PTO	Co	omplete if Known				
				Application Number	09/811,162				
1	INFORMATION DISCLOSURE			Filing Date	March 16, 2001	quac			
		-	NT BY APPLICANT	First Named Inventor	MARTINS-GREEN, Manuela	٦			
· <	. 1	. –		Group Art Unit	1647	ľ			
	S			Examiner Name	Regina M. DeBerry				
9 4 200	2 5	use as	many sheets as necessary)	Attorney Docket Number	407E-000500US				
	ج			Date Submitted	October 31, 2002				
	&Ÿ				<u> </u>	•			
AK Desmouliere, A., Geinoz, A., Gabbiani, F., and G. Gabbiani. 1993. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122:103-111.									
		AL	Devalaraja, R., Nanney, L., Qi 2000. Delayed wound healing	aja, R., Nanney, L., Qian, Q., Du, J., Yu, Y., Devalaraja, M.N., and A. Richmond.					
		AM	Dimitrijevic-Bussod, M., Balzar radiation G1 cell cycle arrest in	retti-Maggi, V., and D. Gadb n human fibroblasts. Cance	pois. 1999. Extracellular matrix and er Res. 59:4843-4847.				
		AN	Doucet, J., and J. Trifaro. 198 polyacrylamide slab gel system	8. A discontinous and high n of high resolution. Anal. E	ly porous sodium dodecyl sulfate- Biochem. 168:265-271.				
		AO	Dunleavy, J., and J. Couchma adhesions in primary fibroblas		ces motile behavior and loss of focal .				
		AP	Chemokines IL-8, GROalpha,	, A., Goebeler, M., Debus, S., Bröcker, E., and R. Gillitzer. 1998. Dalpha, MCP-1, IP-10, and Mig are sequentially and differentially e-specific infiltration of leukocyte subsets in human wound healing. 849-60.					
		AQ	Feugate, J, Li, Q., and Martins differentiation of fibroblasts int Biology. 156:161-172.	Green, M. 2002. The cxc on myofibroblasts and accele	hemokine cCAF stimulates erates wound closure. J. of Cell				
		AR	Gabbiani, G. 1996. The cellular derivation and the life span of the myofibroblast. Pathol. Res.						

AT Gharaee-Kermani, M., Denholm, E., and S. Phan. 1996. Costimulation of fibroblast collagen and transforming growth factor b1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 271:17779-17784.

AU Gupta, S. and J. Singh. 1994. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 127:1121-1127.

AV Hasegawa, M., Sato, S., and K. Takehara. 1999. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 117:159-65.

AW Jester, J., Huang, J., Barry-Lane, P., Kao, W., Petroll, W., and H. Cavanagh. 1999. Transforming growth factor(beta)-mediated corneal myofibroblast differentiation requires actin

Germain, L., Jean, A., Auger, F., and D. Garrel. 1994. Human wound healing fibroblasts

have greater contractile properties than dermal fibroblasts. J. Surg. Res. 57:268-273.

Pract. 192:708-711.

AS

ΑX

	11	//! //				4	1
Examiner Signature	RYM	10189	7)	Date Considered	3	10	03
			\ 				

interleukin 6 and interleukin 8 in scleroderma fibroblasts. J. Rheumatol. 25:296-301.

Kadono, T., Kikuchi, K., Ihn, H., Takehara, K., and K. Tamaki. 1998. Increased production of

and fibronectin assembly. Invest. Ophthalmol. Vis. Sci. 40:1959-67.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0061-0031

Substitute for form 1449A-B/PTO	C	世	2002	
	Application Number	09/811,162	2	
P ANFORMATION DISCLOSURE	Filing Date	March 16, 2001	Ш	. 0
STATEMENT BY APPLICANT	First Named Inventor	MARTINS-GREEN, Manuela	O	
70	Group Art Unit	1647	Ш	0
2002 55	Examiner Name	Regina M. DeBerry	Œ	
se as many sheets as necessary)	Attorney Docket Number	407E-000500US		
2002 G	Date Submitted	October 31, 2002		

NOV

ADENDA		
Me	AY)	Keane, M., Arenberg, D., Lynch, J., Whyte, R., Iannettoni, M., Burdick, M., Wilke, C., Morris, S., Glass, M., DiGiovine, B., Kunkel, S., and R. Strieter. 1997. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 159:1437-43.
	AZ	Khouw, I., van Wachem, P., Plantinga, J., Vujaskovic, Z., Wissink, M., de Leij, L., and M. van Luyn. 1999. TGF-beta and bFGF affect the differentiation of proliferating porcine fibroblasts into myofibroblasts in vitro. Biomaterials 20:1815-1822.
	BA	Lanning, D., Diegelmann, R., Yager, D., Wallace, M., Bagwell, C., and J. Haynes. 2000. Myofibroblast induction with transforming growth factor-beta1 and -beta3 in cutaneous fetal excisional wounds. J. Pediatr. Surg. 35:183-187.
	BB	Luo, Y., D,Amore, P., and M. Dorf. 1996. b-chemokine TCA3 binds to and activates rat vascular smooth muscle cells. J. Immunol. 157:2143-2148.
	ВС	Luster, A., Cardiff, R., MacLean, J., Crowe, K., and R. Granstein. 1998. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proceedings of the Association of American Physicians 110:183-196.
	BD	Mackie, E., Halfter, W., and D. Liverani. 1988. Induction of tenascin in healing wounds. J. Cell Biol. 107:2757-2767.
	BE	Martins-Green, M., and M. Bissell. 1990. Localization of 9E3/CEF-4 in avian tissues: expression is absent in Rous sarcoma virus-induced tumors but is stimulated by injury. J. Cell. Biol. 110:581-595.
	BF	Martins-Green, M., Tilley, C., Schwarz, R., Hatier, C., and M. Bissell. 1991. Wound-factor-induced and cell cycle phase-dependent expression of 9E3/CEF4, the avian gro gene. Cell Regul. 2:739-52.
	BG	Martins-Green, M., Aotaki-Keen, A., Hjelmeland, L., and M. Bissell. 1992. The 9E3 protein: immunolocalization in vivo and evidence for multiple forms in culture. J. Cell Sci. 101:701-707.
	вн	Martins-Green, M., Stoeckle, M., Hampe, A., Wimberly, S., and H. Hanafusa. 1996. The 9E3/CEF4 cytokine: kinetics of secretion, processing by plasmin, and interaction with extracellular matrix. Cytokine 8:448-459.
	BI	Martins-Green, M., and H. Hanafusa. 1997. The 9E3/CEF4 gene and its product the chicken chemotactic and angiogenic factor (cCAF): potential roles in wound healing and tumor development. Cytokine Growth Factor Rev. 8:221-232.
RNS	BJ	Martins-Green, M., and J.E. Feugate. 1998. The 9E3/CEF4 gene product is a chemotactic and angiogenic factor that can initiate the wound healing cascade in vivo. Cytokine 10:522-535.

. 1	7 ,	$1 \bigcirc 1 \bigcirc$				i	
Examiner Signature		1018	15	Date Considered	3/1	10/0	3
			/				


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0851-0031

Subs	titute for	r form 1449A-B/PTO		omplete if Known	200
INFORMATION DISCLOSURE			Application Number	09/811,162	
			Filing Date	March 16, 2001	
P	TEME	NT BY APPLICANT	First Named Inventor	MARTINS-GREEN, Manuela	
			Group Art Unit	1647 U] 9
ຸ້ດ	1		Examiner Name	Regina M. DeBerry	-
2002 G	use as	many sheets as necessary)	Attorney Docket Number	407E-000500US	
.57	<i>'</i>		Date Submitted	October 31, 2002	
BKOTIL					
KN)	ВК	Martins-Green, M., and T. Kel gene product): Its angiogenic 10:819-830.	ly. 1998. The chicken cher properties residue in the C-t	notactic and angiogenic factor (9E3 terminus of the molecule. Cytokine	
	BL	Masur, S., Dewal, H., Dinh, T. differentiate from fibroblasts w 4223.	., Erenburg, I., and S. Petrid hen plated at low density. I	ou. 1996. Myofibroblasts Proc. Natl. Acad. Sci. USA 93:4219-	
	ВМ	Nanney, L., Muellaer, S., Buel melanoma growth stimulatory in human wound repair. Am.	activity or growth-regulated	chmond. 1995. Distribution of gene and the interleukin-8 receptor	
	BN	Nedelec, B., Dodd, C., Scott, on guinea pig wound closure a Repair. Reg. 6:202-212.	cott, P., Ghahary, A., and E. Tredget. 1998. Effect of interferon-a2b sure and the expression of cytoskeletal proteins in vivo. Wound		
	во		, Nanney, L., Arrindell, S., Russell, S., Trupin, J., and A. Richmond. emokine receptor expression in keloid and normal fibroblasts. 371-382.		
	BP	Powell, D., Mifflin, R., Valentic I. Paracrine cells important in	ch, J., Crowe, S., Saada, J., health and disease. Am. J	and A. West. 1999. Myofibroblasts Physiol. 277:C1-19.	•
	BQ	Prieschl, E.E., Kulmburg, P.A. Int. Arch. Allergy Immunol. 10		The nomenclature of chemokines.	
	BR		nulatory activity (MGSA/gro)	(iessig, V., and J. Schroder. 1997. on keratinocyte function in wound	
	BS	Serini, G., and G. Gabbiani. 1 modulation. Exp. Cell Res. 25		broblast activity and phenotypic	
	ВТ	Stoeckle, M., and K. Barker. 1 proteins: mediators of the infla	990. Two burgeoning familiammatory response. New B	es of platelet factor 4-related liol. 2:313-323.	
	BU	Strieter, R., Polverini, P., Arer regulators of angiogenesis. S		995. Role of CXC chemokines as	
	BV	Weber, M., Uguccioni, M., Bay the NH2-terminal residue con- basophil release to an eosino	verts monocyte chemotactic	and C. Dahinden. 1996. Deletion of protein 1 from an activator of D. Med. 183:681-685.	
1W	BW	Youngs, S., Ali, S., Taub, D., a in human breast carcinoma ce		kines induce migrational responses 57-266.	

	10.0			1)
Examiner Signature	NUPS)	Date Considered	3,	11/103
			τ	

*EXAMINER: Initial if reference considered, whether or not sitation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



	Substitute for form 1449A-B/PTO P NFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		<u>_</u>	
				Application Number	09/811,162		_ 9
101				Filing Date	March 16, 2001	7	₹
				First Named Inventor	MARTINS-GREEN, Manuela	\leq	
NOV O				Group Art Unit	1647	Щ	,
	4 2002 5	1		Examiner Name	Regina M. DeBerry	∇	
	(use as many sheets as necessary)			Attorney Docket Number	407E-000500US	Ш	₫
(Z)				Date Submitted	October 31, 2002	$\underline{\mathbf{r}}$	
AUE.	Aw	BX	Zhang, Y., Zhang, Y., Ogata, M., Chen, P., Harada, A., Hashimoto S., and K. Matsushima. 1999. Transforming growth factor-b1 polarizes murine hematopoietic progenitor cells to generate Langerhans cell-like dendritic cells through a monocyte/macrophage differentiation pathway. Blood 93:1208-1220. Zlotnik, A., Morales, J., and J. Hedrick. 1999. Recent advances in chemokines and				
		BY Zlotnik, A., Morales, J., and J. Hedrick. 1999. Recent advances in chemokines and chemokine receptors. Crit. Rev. Immol. 19:1-47.					

Examiner Signature Date Considered 3 10 03